Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective phase II clinical trial to observe the efficacy and safety of
Camrelizumab combined with AVD in the first-line treatment for patients with advanced
classical Hodgkin's lymphoma.